Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
about
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceEstrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective[Cathepsin K antagonists: preclinical and clinical data].Observations following discontinuation of long-term denosumab therapy.Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.The effect of antiresorptives on bone quality.Application of a mechanism-based disease systems model for osteoporosis to clinical data.Coping with time scales in disease systems analysis: application to bone remodelingBenefits and risks of sex hormone replacement in postmenopausal women.Denosumab in postmenopausal osteoporosis: what the clinician needs to know.The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).Combination/sequential therapy in osteoporosis.The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials.Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.Osteoporosis prevention and therapy: preserving and building strength through bone quality.Osteoporosis: how should it be treated?Estrogen therapy for postmenopausal osteoporosis.Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trialCare of the menopausal patient: a nurse practitioner's view.Prevalent and Emerging Therapies for Osteoporosis.Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of womenPharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women.Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.Bone turnover assessment: a good surrogate marker?Bone turnover markers: use in osteoporosis.Acute hypophosphatasemia.How long should we treat?The use of bisphosphonates in women: when to use and when to stop.Bisphosphonate drug holidays--when, why and for how long?Using Osteoporosis Therapies in Combination.Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?Vignettes in osteoporosis: a road map to successful therapeutics.Estrogen treatment does not reduce fractures?Potential clinical and economic impact of nonadherence with osteoporosis medications.
P2860
Q24242258-10EF1A00-6C4B-4086-9887-0A3D1DE0B8A9Q24644708-6DFAF6F6-145F-4BE9-ABCB-F900A0EE9951Q24658109-4A95CF44-8CB5-4CB6-8771-0995A4B4C4E7Q26864207-DF0A47A3-7E28-4EAC-BC23-4B5880156B50Q30883642-B846B8F4-5ED5-4CA8-873E-AC68E6137424Q33563846-4B9C41A8-57AA-4DA5-88F8-7B27C4215EADQ33661422-ABAC0537-96F3-4EC9-A9CE-02103D9C24E0Q33715141-CD964ADC-9293-4ED9-9A60-A45021C39DD8Q33896122-B70CDA6A-886D-47FF-AAC5-4DE02F1301BAQ34546981-A82B2DB9-8D3C-446A-9DB6-CA7DFBEB7A0DQ35591581-707B3B53-660D-4DE2-9E67-CE706D712A2DQ35910115-A7094040-7FF4-488F-AC11-20832F1CC9CBQ36056922-6CCC153C-C212-4D72-A930-598A77D1D9E8Q36190027-440FBC8B-79C5-485A-83E9-61D438AEB8E3Q36203344-366FA4F0-02CD-4BCC-962D-81037A8BC21BQ36215878-7B9BB8ED-40F6-4AA2-884B-06FBE082DBEAQ36416737-E1B6AA61-03F0-4006-B8DB-16D986CC9A15Q36565785-14EC9B0A-7F64-4C61-9746-C36568BC4F1CQ36583646-1227FB99-86A9-4D73-BF56-457BD26F9571Q36658946-1BE1956D-A88D-461E-B704-D3B906755E0AQ36742845-A9373A8E-F78D-403E-8190-CBEF00BDFC84Q36892860-5FD0206E-C757-4321-AE7E-495300CBC312Q37038535-62F3F522-EBC7-4C6D-AB0B-F5AD7837DCAEQ37121645-BD6B007A-3BC6-4853-80F9-72F25FB9054BQ37197298-DE9FD0A0-8012-4F60-92AE-D80DF091812DQ37401847-3EBC85E3-A721-4226-A339-E9AEFDC66B9DQ37430269-61A2AD0A-7380-445F-BDC0-716EFACBA10EQ37540090-230EE355-10EC-469C-8705-4453D4DB9338Q37672603-BD5BE00B-28D1-42DB-8D4C-FCE5C0405C69Q37756573-308244F7-EF9E-462C-B177-F5F2536CAD3DQ38016073-F6BB0AFF-BCC5-49FC-BB2D-8CA6FDF0F4AEQ38126360-8401926D-71FC-434B-BFA7-708BCF435761Q38199355-F791D993-A2AB-4FD5-B9C8-A7B3B5E888C5Q38584336-EA9709EC-7100-485B-87CB-57371F15D708Q38617760-D3CB22F8-299E-44AA-BCDE-EBE59E0E8FB7Q39408210-13DD0E8A-37E4-4C98-B0B0-05476039E41CQ39643651-90DB98B4-84E8-4D19-A174-98325E02B988Q40534367-4C09BF09-7CA3-404B-B5D6-A6812D7AA701Q42952699-027C9B6E-5A67-41A8-BA8E-D6A2CEF06796Q43141937-C1B1DB88-6D86-42DD-AC00-BBA9E6B190F5
P2860
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Significant differential effec ...... ind, placebo-controlled trial.
@en
Significant differential effec ...... ind, placebo-controlled trial.
@nl
type
label
Significant differential effec ...... ind, placebo-controlled trial.
@en
Significant differential effec ...... ind, placebo-controlled trial.
@nl
prefLabel
Significant differential effec ...... ind, placebo-controlled trial.
@en
Significant differential effec ...... ind, placebo-controlled trial.
@nl
P2093
P1476
Significant differential effec ...... ind, placebo-controlled trial.
@en
P2093
Amarjot Kaur
Anthony L Mulloy
Antonio Lombardi
Clark McKeever
Henry G Bone
Michael A Bolognese
Michael Davidson
Norman H Bell
Norman Heyden
P304
P356
10.7326/0003-4819-137-11-200212030-00008
P407
P577
2002-12-01T00:00:00Z